Can04 (Not yet branded)
Other Medications
Description
CAN04 is a monoclonal antibody that targets the IL1RAP (Interleukin-1 Receptor Accessory Protein) pathway in cancer treatment. This agent is being developed for patients with advanced solid tumors, including colorectal cancer, through early-phase clinical trials. CAN04 represents a novel approach to cancer immunotherapy by targeting inflammatory signaling pathways that support tumor growth and immune evasion.
Mechanism of Action
CAN04 works by binding to IL1RAP, a co-receptor protein involved in interleukin-1 and interleukin-33 signaling pathways that promote tumor inflammation and immune suppression. By blocking IL1RAP, the antibody aims to reduce pro-tumorigenic inflammatory signals while potentially enhancing anti-tumor immune responses. This mechanism targets both the tumor microenvironment and cancer stem cell populations that express high levels of IL1RAP.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.